has approved the BYDUREON® Pen (exenatide extended-release for injectable suspension) 2 mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes.

The Bydureon BCise autoinjector pen dosage is 2 mg under the skin once every 7 days. You can inject your dose at any time of the day. Your dosing frequency is just one dose every 7 days (once per ...

AstraZeneca's exenatide extended release for injectable suspension (Bydureon Pen) 2 mg is intended for once-weekly use as an adjunct to diet and exercise in the treatment of adults with type 2 ...

product design and development firm Cambridge Consultants in association with AstraZeneca have developed Bydureon pen, an exenatide extended-release for injectable suspension 2 mg. Bydureon first of ...

The Food and Drug Administration (FDA) has expanded the approval of the Bydureon BCise (exenatide extended-release) injection ... assigned 2:1 to receive exenatide extended-release 2 mg ...

AstraZeneca ($AZN) won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The ...

It could spell the end of sufferers having to inject themselves with ... the final guidance in February. Bydureon provides the first treatment for type 2 diabetes which can be administered just ...